A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy

The Coronavirus Vaccines R&D Roadmap Taskforce

doi:10.1016/j.vaccine.2023.02.032

A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy

The Coronavirus Vaccines R&D Roadmap Taskforce

Center for Infectious Disease Research and Policy

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Broadly protective coronavirus vaccines are an important tool for protecting against future SARS-CoV-2 variants and could play a critical role in mitigating the impact of future outbreaks or pandemics caused by novel coronaviruses. The Coronavirus Vaccines Research and Development (R&D) Roadmap (CVR) is aimed at promoting the development of such vaccines. The CVR, funded by the Bill & Melinda Gates Foundation and The Rockefeller Foundation, was generated through a collaborative and iterative process, which was led by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota and involved 50 international subject matter experts and recognized leaders in the field. This report summarizes the major issues and areas of research outlined in the CVR and identifies high-priority milestones. The CVR covers a 6-year timeframe and is organized into five topic areas: virology, immunology, vaccinology, animal and human infection models, and policy and finance. Included in each topic area are key barriers, gaps, strategic goals, milestones, and additional R&D priorities. The roadmap includes 20 goals and 86 R&D milestones, 26 of which are ranked as high priority. By identifying key issues, and milestones for addressing them, the CVR provides a framework to guide funding and research campaigns that promote the development of broadly protective coronavirus vaccines.

Original language	English (US)
Pages (from-to)	2101-2112
Number of pages	12
Journal	Vaccine
Volume	41
Issue number	13
DOIs	https://doi.org/10.1016/j.vaccine.2023.02.032
State	Published - Mar 24 2023

Bibliographical note

Funding Information:
Funding: The work for this project was completed with funding from the Bill & Melinda Gates Foundation (Award #: INV-040729) and The Rockefeller Foundation (Award #: 2022 HTH 002). The findings and conclusions contained within this report are those of the authors and do not necessarily reflect the positions or policies of the Bill & Melinda Gates Foundation or The Rockefeller Foundation.

Publisher Copyright:
© 2023 The Author(s)

Keywords

Broadly protective coronavirus vaccines
COVID-19 vaccines
Coronavirus
Coronavirus vaccines
Pandemic preparedness
Roadmap
Vaccine research

PubMed: MeSH publication types

Journal Article
Review
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.vaccine.2023.02.032

OpenUrl availability

Full text

Cite this

@article{271cff413d174407ae935878dd480375,

title = "A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy",

abstract = "Broadly protective coronavirus vaccines are an important tool for protecting against future SARS-CoV-2 variants and could play a critical role in mitigating the impact of future outbreaks or pandemics caused by novel coronaviruses. The Coronavirus Vaccines Research and Development (R&D) Roadmap (CVR) is aimed at promoting the development of such vaccines. The CVR, funded by the Bill & Melinda Gates Foundation and The Rockefeller Foundation, was generated through a collaborative and iterative process, which was led by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota and involved 50 international subject matter experts and recognized leaders in the field. This report summarizes the major issues and areas of research outlined in the CVR and identifies high-priority milestones. The CVR covers a 6-year timeframe and is organized into five topic areas: virology, immunology, vaccinology, animal and human infection models, and policy and finance. Included in each topic area are key barriers, gaps, strategic goals, milestones, and additional R&D priorities. The roadmap includes 20 goals and 86 R&D milestones, 26 of which are ranked as high priority. By identifying key issues, and milestones for addressing them, the CVR provides a framework to guide funding and research campaigns that promote the development of broadly protective coronavirus vaccines.",

keywords = "Broadly protective coronavirus vaccines, COVID-19 vaccines, Coronavirus, Coronavirus vaccines, Pandemic preparedness, Roadmap, Vaccine research",

author = "{The Coronavirus Vaccines R&D Roadmap Taskforce} and Moore, {Kristine A.} and Tabitha Leighton and Ostrowsky, {Julia T.} and Anderson, {Cory J.} and Danila, {Richard N.} and Ulrich, {Angela K.} and Lackritz, {Eve M.} and Mehr, {Angela J.} and Baric, {Ralph S.} and Baylor, {Norman W.} and Gellin, {Bruce G.} and Gordon, {Jennifer L.} and Florian Krammer and Stanley Perlman and Rees, {Helen V.} and Melanie Saville and Weller, {Charlotte L.} and Osterholm, {Michael T.}",

note = "Funding Information: Funding: The work for this project was completed with funding from the Bill & Melinda Gates Foundation (Award #: INV-040729) and The Rockefeller Foundation (Award #: 2022 HTH 002). The findings and conclusions contained within this report are those of the authors and do not necessarily reflect the positions or policies of the Bill & Melinda Gates Foundation or The Rockefeller Foundation. Publisher Copyright: {\textcopyright} 2023 The Author(s)",

year = "2023",

month = mar,

day = "24",

doi = "10.1016/j.vaccine.2023.02.032",

language = "English (US)",

volume = "41",

pages = "2101--2112",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "13",

}

TY - JOUR

T1 - A research and development (R&D) roadmap for broadly protective coronavirus vaccines

T2 - A pandemic preparedness strategy

AU - The Coronavirus Vaccines R&D Roadmap Taskforce

AU - Moore, Kristine A.

AU - Leighton, Tabitha

AU - Ostrowsky, Julia T.

AU - Anderson, Cory J.

AU - Danila, Richard N.

AU - Ulrich, Angela K.

AU - Lackritz, Eve M.

AU - Mehr, Angela J.

AU - Baric, Ralph S.

AU - Baylor, Norman W.

AU - Gellin, Bruce G.

AU - Gordon, Jennifer L.

AU - Krammer, Florian

AU - Perlman, Stanley

AU - Rees, Helen V.

AU - Saville, Melanie

AU - Weller, Charlotte L.

AU - Osterholm, Michael T.

N1 - Funding Information: Funding: The work for this project was completed with funding from the Bill & Melinda Gates Foundation (Award #: INV-040729) and The Rockefeller Foundation (Award #: 2022 HTH 002). The findings and conclusions contained within this report are those of the authors and do not necessarily reflect the positions or policies of the Bill & Melinda Gates Foundation or The Rockefeller Foundation. Publisher Copyright: © 2023 The Author(s)

PY - 2023/3/24

Y1 - 2023/3/24

N2 - Broadly protective coronavirus vaccines are an important tool for protecting against future SARS-CoV-2 variants and could play a critical role in mitigating the impact of future outbreaks or pandemics caused by novel coronaviruses. The Coronavirus Vaccines Research and Development (R&D) Roadmap (CVR) is aimed at promoting the development of such vaccines. The CVR, funded by the Bill & Melinda Gates Foundation and The Rockefeller Foundation, was generated through a collaborative and iterative process, which was led by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota and involved 50 international subject matter experts and recognized leaders in the field. This report summarizes the major issues and areas of research outlined in the CVR and identifies high-priority milestones. The CVR covers a 6-year timeframe and is organized into five topic areas: virology, immunology, vaccinology, animal and human infection models, and policy and finance. Included in each topic area are key barriers, gaps, strategic goals, milestones, and additional R&D priorities. The roadmap includes 20 goals and 86 R&D milestones, 26 of which are ranked as high priority. By identifying key issues, and milestones for addressing them, the CVR provides a framework to guide funding and research campaigns that promote the development of broadly protective coronavirus vaccines.

AB - Broadly protective coronavirus vaccines are an important tool for protecting against future SARS-CoV-2 variants and could play a critical role in mitigating the impact of future outbreaks or pandemics caused by novel coronaviruses. The Coronavirus Vaccines Research and Development (R&D) Roadmap (CVR) is aimed at promoting the development of such vaccines. The CVR, funded by the Bill & Melinda Gates Foundation and The Rockefeller Foundation, was generated through a collaborative and iterative process, which was led by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota and involved 50 international subject matter experts and recognized leaders in the field. This report summarizes the major issues and areas of research outlined in the CVR and identifies high-priority milestones. The CVR covers a 6-year timeframe and is organized into five topic areas: virology, immunology, vaccinology, animal and human infection models, and policy and finance. Included in each topic area are key barriers, gaps, strategic goals, milestones, and additional R&D priorities. The roadmap includes 20 goals and 86 R&D milestones, 26 of which are ranked as high priority. By identifying key issues, and milestones for addressing them, the CVR provides a framework to guide funding and research campaigns that promote the development of broadly protective coronavirus vaccines.

KW - Broadly protective coronavirus vaccines

KW - COVID-19 vaccines

KW - Coronavirus

KW - Coronavirus vaccines

KW - Pandemic preparedness

KW - Roadmap

KW - Vaccine research

UR - http://www.scopus.com/inward/record.url?scp=85149685903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85149685903&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2023.02.032

DO - 10.1016/j.vaccine.2023.02.032

M3 - Review article

C2 - 36870874

AN - SCOPUS:85149685903

SN - 0264-410X

VL - 41

SP - 2101

EP - 2112

JO - Vaccine

JF - Vaccine

IS - 13

ER -

A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this